Cavion LLC   Report issue

For profit Phase 1 Phase 2
Founded: Charlottesville VA United States (2003)
Status: Acquired by Jazz Pharmaceuticals (2019)

Organization Overview

First Clinical Trial
2012
NCT01550458
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cavion, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

cx-8998 (3 trials)

Drugs in Phase 1 Trials (3)

fluorothymidine (1 trial)

mibefradil (Posicor) (3 trials)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Nervous System Neoplasms (Phase 1)

Epilepsy (Phase 2)

Epilepsy, Absence (Phase 2)

Epilepsy, Generalized (Phase 2)

Essential Tremor (Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Nervous System Neoplasms (Phase 1)

Parkinson Disease (Phase 2)

Seizures (Phase 2)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4